<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959971</url>
  </required_header>
  <id_info>
    <org_study_id>PDY13670</org_study_id>
    <secondary_id>U1111-1141-4567</secondary_id>
    <nct_id>NCT01959971</nct_id>
  </id_info>
  <brief_title>Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol</brief_title>
  <official_title>A Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the effects of subcutaneous (SC) doses of alirocumab on the elimination (measured
      by Fractional Clearance Rate (FCR)) of apolipoprotein B (apoB) in low density lipoprotein
      (LDL) in adults with mildly elevated LDL-cholesterol (LDL-C).

      Secondary Objectives:

      To assess the effects of SC doses of alirocumab on:

        -  Various parameters of the metabolism and turnover in plasma of different lipoproteins

        -  Plasma lipids concentration: total cholesterol, high density lipoprotein cholesterol
           (HDL-C), triglycerides, low density lipoprotein cholesterol (LDL-C), apoB,
           lipoprotein(a) (Lp(a))

        -  Lipoprotein particle size profile

        -  PCSK9 (free and total) concentrations in serum To assess safety and tolerability of
           alirocumab. To assess emergence of anti-alirocumab antibodies. To document serum
           alirocumab concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study per subject is 26 weeks, including a screening period of ≤ 4
      weeks, placebo treatment period of 4 weeks, alirocumab treatment period of 10 weeks, and a
      follow up period of 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-sequence crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in Fractional Clearance Rate of apolipoprotein B (apoB) in Low Density Lipoproteins (pools/day) in plasma during alirocumab treatment</measure>
    <time_frame>baseline and at 12 days after last dose of alirocumab</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lipids turnover parameters measured in isolated Very Low Density Lipoproteins (VLDL), Intermediate Density Lipoproteins (IDL), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL)</measure>
    <time_frame>baseline and at 12 days after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-heparin hepatic lipase and lipoprotein lipase activities</measure>
    <time_frame>baseline and at 2 days after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids and apolipoproteins in plasma lipids panel</measure>
    <time_frame>baseline and at 2 days and at 11 days after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Lipoprotein particle size profiles</measure>
    <time_frame>baseline and at 2 days and at 11 days after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of serum concentrations of PCSK9</measure>
    <time_frame>baseline and up to 2 weeks after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety parameters (clinical laboratory, ECG, vital signs)</measure>
    <time_frame>up to 10 weeks after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the serum concentration of alirocumab</measure>
    <time_frame>baseline and up to 2 weeks after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the serum concentration of anti-alirocumab antibodies</measure>
    <time_frame>baseline and up to 10 weeks after last dose of alirocumab</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo - Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab</intervention_name>
    <description>Pharmaceutical form:Solution for injection
Route of administration: Subcutaneous</description>
    <arm_group_label>Placebo - Alirocumab</arm_group_label>
    <other_name>SAR236553</other_name>
    <other_name>REGN727</other_name>
    <other_name>Praluent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Solution for injection
Route of administration: Subcutaneous</description>
    <arm_group_label>Placebo - Alirocumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Generally healthy; LDL-C level in serum or plasma ≥ 100 mg/dL and &lt; 190 mg/dL at Screening.

        Exclusion criteria:

          -  LDL-C ≥ 160 mg/dL at Screening if more than 2 major Coronary Heart Disease risk
             factors, as defined in National Cholesterol Education Program guidelines.

          -  Receiving treatment of any kind for hyperlipidemia within 6 weeks of enrollment.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16.</citation>
    <PMID>27986651</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

